Last reviewed · How we verify
Bortezomib, Rituximab, Dexamethasone
Bortezomib, Rituximab, Dexamethasone is a Proteasome inhibitor Small molecule drug developed by Meletios A. Dimopoulos. It is currently in Phase 2 development for Multiple myeloma, Mantle cell lymphoma. Also known as: BDR.
Proteasome inhibitor
Proteasome inhibitor Used for Multiple myeloma, Mantle cell lymphoma.
At a glance
| Generic name | Bortezomib, Rituximab, Dexamethasone |
|---|---|
| Also known as | BDR |
| Sponsor | Meletios A. Dimopoulos |
| Drug class | Proteasome inhibitor |
| Target | 20S proteasome |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bortezomib is a proteasome inhibitor that blocks the action of proteasomes, which are complexes that break down proteins in cells. This leads to an accumulation of defective proteins, which can trigger apoptosis in cancer cells.
Approved indications
- Multiple myeloma
- Mantle cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Diarrhea
- Nausea
- Vomiting
- Pyrexia
- Headache
- Dizziness
Key clinical trials
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (PHASE2)
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (PHASE2)
- The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia (PHASE4)
- Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients (PHASE2)
- Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies (EARLY_PHASE1)
- Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia (PHASE3)
- R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia (PHASE2)
- Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bortezomib, Rituximab, Dexamethasone CI brief — competitive landscape report
- Bortezomib, Rituximab, Dexamethasone updates RSS · CI watch RSS
- Meletios A. Dimopoulos portfolio CI
Frequently asked questions about Bortezomib, Rituximab, Dexamethasone
What is Bortezomib, Rituximab, Dexamethasone?
Bortezomib, Rituximab, Dexamethasone is a Proteasome inhibitor drug developed by Meletios A. Dimopoulos, indicated for Multiple myeloma, Mantle cell lymphoma.
How does Bortezomib, Rituximab, Dexamethasone work?
Proteasome inhibitor
What is Bortezomib, Rituximab, Dexamethasone used for?
Bortezomib, Rituximab, Dexamethasone is indicated for Multiple myeloma, Mantle cell lymphoma.
Who makes Bortezomib, Rituximab, Dexamethasone?
Bortezomib, Rituximab, Dexamethasone is developed by Meletios A. Dimopoulos (see full Meletios A. Dimopoulos pipeline at /company/meletios-a-dimopoulos).
Is Bortezomib, Rituximab, Dexamethasone also known as anything else?
Bortezomib, Rituximab, Dexamethasone is also known as BDR.
What drug class is Bortezomib, Rituximab, Dexamethasone in?
Bortezomib, Rituximab, Dexamethasone belongs to the Proteasome inhibitor class. See all Proteasome inhibitor drugs at /class/proteasome-inhibitor.
What development phase is Bortezomib, Rituximab, Dexamethasone in?
Bortezomib, Rituximab, Dexamethasone is in Phase 2.
What are the side effects of Bortezomib, Rituximab, Dexamethasone?
Common side effects of Bortezomib, Rituximab, Dexamethasone include Neutropenia, Thrombocytopenia, Anemia, Fatigue, Diarrhea, Nausea.
What does Bortezomib, Rituximab, Dexamethasone target?
Bortezomib, Rituximab, Dexamethasone targets 20S proteasome and is a Proteasome inhibitor.
Related
- Drug class: All Proteasome inhibitor drugs
- Target: All drugs targeting 20S proteasome
- Manufacturer: Meletios A. Dimopoulos — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Multiple myeloma
- Indication: Drugs for Mantle cell lymphoma
- Also known as: BDR
- Compare: Bortezomib, Rituximab, Dexamethasone vs similar drugs
- Pricing: Bortezomib, Rituximab, Dexamethasone cost, discount & access